Drug intelligence / Profile preview

OR-102

Development stage: Preclinical
Lead developer: Ornovi

Overview

OR-102 is a preclinical-stage drug candidate being developed by Ornovi. As of early 2024, the specific therapeutic target, molecular modality, and primary disease indications for OR-102 remain undisclosed. Ornovi has indicated that it is actively pursuing exclusive licensing rights for this asset. It is the second program listed in the company's pipeline, following their lead dual JAK3/ITK inhibitor program, OR-101.

Beyond the preview

Go deeper on OR-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OR-102.